Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioPlus Acquisition Corp.BIOS · Entity 112459 | Director | December 02, 2021 | December 03, 2021 |
| Cyclo Therapeutics, Inc.CYTH · Entity 82635 | Director | February 27, 2025 | March 03, 2025 |
| GT Biopharma, Inc.GTBP · Entity 7878 | Director · Chief Executive Officer | November 16, 2017 | March 16, 2018 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Financial Officer | April 23, 2026 | April 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioPlus Acquisition Corp.
Report date December 02, 2021 · Filed December 03, 2021
This filing explicitly reported no securities owned.
Cyclo Therapeutics, Inc.
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,346 |
Reported balance
After 2025-02-27 transaction · row 1
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 28,597 · Balance 136,346 F1: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025.
GT Biopharma, Inc.
Report date November 16, 2017 · Filed March 16, 2018
This filing explicitly reported no securities owned.
Pacira BioSciences, Inc.
Report date April 23, 2026 · Filed April 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,341 |
Ending reported balance
After 2026-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-23 · Exercise / conversion · Acquired 12,941 · Balance 118,282 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Row 2 · 2026-04-23 · Sale · Disposed 12,941 · Balance 105,341 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2034-11-04 | Direct | 150,000 |
Reported balance
After 2026-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-23 · Exercise / conversion · Disposed 12,941 · Balance 150,000 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F3: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Applied Molecular Transport Inc.
Report date December 27, 2023 · Filed December 28, 2023
Section 16 reporting ended · disclosed 2023-12-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 1
1 source rowRow 1 · 2023-12-27 · Disposition to issuer · Disposed 545,499 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration"). F2: Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 72,606 shares of Cyclo common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.61 · Expires 2030-03-30 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.61 · Expires 2031-03-01 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-27 · Disposition to issuer · Disposed 63,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.29 · Expires 2032-02-15 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-12-27 · Disposition to issuer · Disposed 94,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2032-05-16 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-27 · Disposition to issuer · Disposed 84,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2033-03-24 | Direct | 0 |
Reported balance
After 2023-12-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-27 · Disposition to issuer · Disposed 668,000 · Balance 0 F4: Pursuant to the Merger Agreement, this option was exchanged for an option covering 88,910 shares of Cyclo Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration").
F2: Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 72,606 shares of Cyclo common stock.
F3: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
F4: Pursuant to the Merger Agreement, this option was exchanged for an option covering 88,910 shares of Cyclo Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2026 Filed Apr 25, 2026 00:41 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,941 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001628280-26-027287 · wk-form4_1777077683.xml · derivative · entry 3 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 12,941 shares Expires 2034-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. F1 · derivative.underlying_shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Read SEC document |
| April 23, 2026 Filed Apr 25, 2026 00:41 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 12,941 | $25.16 | $325,595.56 |
DisclosureSEC source: 0001628280-26-027287 · wk-form4_1777077683.xml · nonDerivative · entry 2 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,341 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 23, 2026 Filed Apr 25, 2026 00:41 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 12,941 | $16.45 | $212,879.45 |
DisclosureSEC source: 0001628280-26-027287 · wk-form4_1777077683.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · derivative · entry 9 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,941 Underlying: Common Stock · 1,500 shares Expires 2034-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. F1 · derivative.underlying_shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,500 | $25.01 | $37,515.00 |
DisclosureSEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 6 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,341 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 1,500 | $16.45 | $24,675.00 |
DisclosureSEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 5 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,845 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · derivative · entry 8 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,441 Underlying: Common Stock · 2,845 shares Expires 2034-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. F1 · derivative.underlying_shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,845 | $25.01 | $71,153.45 |
DisclosureSEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 4 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,341 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,845 | $16.45 | $46,800.25 |
DisclosureSEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 3 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Read SEC document |
| April 20, 2026 Filed Apr 23, 2026 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,714 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · derivative · entry 7 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,286 Underlying: Common Stock · 7,714 shares Expires 2034-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. F1 · derivative.underlying_shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Read SEC document |
| April 20, 2026 Filed Apr 23, 2026 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 7,714 | $25.14 | $193,929.96 |
DisclosureSEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 2 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,341 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3. Read SEC document |
| April 20, 2026 Filed Apr 23, 2026 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,714 | $16.45 | $126,895.30 |
DisclosureSEC source: 0001628280-26-026669 · wk-form4_1776902593.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:02 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 49,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-008080 · wk-form4_1771016540.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,341 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 02:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,104 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001628280-25-056645 · wk-form4_1765507617.xml · derivative · entry 6 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 9,104 shares Expires 2034-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 02:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 9,104 | $25.14 | $228,874.56 |
DisclosureSEC source: 0001628280-25-056645 · wk-form4_1765507617.xml · nonDerivative · entry 4 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,250 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 02:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 9,104 | $16.45 | $149,760.80 |
DisclosureSEC source: 0001628280-25-056645 · wk-form4_1765507617.xml · nonDerivative · entry 3 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| December 09, 2025 Filed Dec 12, 2025 02:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,896 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001628280-25-056645 · wk-form4_1765507617.xml · derivative · entry 5 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,104 Underlying: Common Stock · 15,896 shares Expires 2034-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| December 09, 2025 Filed Dec 12, 2025 02:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 15,896 | $25.03 | $397,876.88 |
DisclosureSEC source: 0001628280-25-056645 · wk-form4_1765507617.xml · nonDerivative · entry 2 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,250 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3. Read SEC document |
| December 09, 2025 Filed Dec 12, 2025 02:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 15,896 | $16.45 | $261,489.20 |
DisclosureSEC source: 0001628280-25-056645 · wk-form4_1765507617.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 21:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 12,060 | $22.09 | $266,405.40 |
DisclosureSEC source: 0001628280-25-052038 · wk-form4_1763068400.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,250 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| October 31, 2025 Filed Nov 3, 2025 22:41 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 6,690 | $21.38 | $143,032.20 |
DisclosureSEC source: 0001628280-25-048393 · wk-form4_1762209691.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,310 F1 · kind: Represents shares withheld by the issuer to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 11:44 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 28,597 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-005850 · rdgdoc.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,346 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 14:10 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 17,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-035588 · rdgdoc.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,749 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the third quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $0.66 per share of common stock on November 14, 2024 Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:42 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001396814-24-000135 · wk-form4_1730842931.xml · derivative · entry 2 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-11-04 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:42 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000135 · wk-form4_1730842931.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on November 1, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 13:49 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 9,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-027329 · rdgdoc.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,521 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the second quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $1.26 per share of common stock on August 16, 2024. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:09 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to Buy) · Derivative | 15,562 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001437749-24-019344 · rdgdoc.xml · derivative · entry 2 Cross Shawn · CIK 0001734779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,562 Underlying: Common Stock · 15,562 shares Expires 2034-06-03 F2 · derivative.exercise_date: The option vests over a one year period in equal quarterly installments. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:09 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 8,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-019344 · rdgdoc.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,493 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the first quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $1.28 per share of common stock on June 3, 2024. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 21:50 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to buy) · Derivative | 88,910 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001437749-23-035527 · rdgdoc.xml · derivative · entry 2 Cross Shawn · CIK 0001734779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,910 Underlying: Common Stock · 88,910 shares Expires 2024-12-27 F1 · price: On September 21, 2023, Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. ("Merger Sub"), and Applied Molecular Transport, Inc. ("AMTI") entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into AMTI, with AMTI continuing as a wholly owned subsidiary of Cyclo and the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger on December 27, 2023, the Reporting Person received shares of Cyclo common stock in exchange for shares of AMTI common stock and options to acquire shares of Cyclo common stock in exchange for options to acquire shares of AMTI common stock, each based on the exchange ratio determined by the Merger Agreement. All AMTI restricted stock units held by the Reporting Person were fully settled prior to the effective time of the Merger. F2 · derivative.exercise_date: The options were fully vested upon the closing of the Merger Agreement. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 21:50 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 72,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-035527 · rdgdoc.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,606 F1 · price: On September 21, 2023, Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. ("Merger Sub"), and Applied Molecular Transport, Inc. ("AMTI") entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into AMTI, with AMTI continuing as a wholly owned subsidiary of Cyclo and the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger on December 27, 2023, the Reporting Person received shares of Cyclo common stock in exchange for shares of AMTI common stock and options to acquire shares of Cyclo common stock in exchange for options to acquire shares of AMTI common stock, each based on the exchange ratio determined by the Merger Agreement. All AMTI restricted stock units held by the Reporting Person were fully settled prior to the effective time of the Merger. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 17:29 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Disposition to issuerStock Option (Right to Buy) · Derivative | 668,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001209191-23-059929 · doc4.xml · derivative · entry 6 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 668,000 shares Expires 2033-03-24 F4 · derivative.exercise_date: Pursuant to the Merger Agreement, this option was exchanged for an option covering 88,910 shares of Cyclo Common Stock. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 17:29 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Disposition to issuerStock Option (Right to Buy) · Derivative | 84,000 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-23-059929 · doc4.xml · derivative · entry 5 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,000 shares Expires 2032-05-16 F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 17:29 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Disposition to issuerStock Option (Right to Buy) · Derivative | 94,500 | $0.00 Strike: $8.29 | $0.00 |
DisclosureSEC source: 0001209191-23-059929 · doc4.xml · derivative · entry 4 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,500 shares Expires 2032-02-15 F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 17:29 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Disposition to issuerStock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $56.61 | $0.00 |
DisclosureSEC source: 0001209191-23-059929 · doc4.xml · derivative · entry 3 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,000 shares Expires 2031-03-01 F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 17:29 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Disposition to issuerStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0001209191-23-059929 · doc4.xml · derivative · entry 2 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2030-03-30 F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 17:29 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | Disposition to issuerCommon Stock | 545,499 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-059929 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration"). F2 · price: Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 72,606 shares of Cyclo common stock. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 16:21 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 110,802 | $0.16 | $18,116.13 |
DisclosureSEC source: 0001209191-23-056587 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,499 F1 · kind: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1634 to $0.164, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 17:36 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 90,447 | $0.16 | $14,525.79 |
DisclosureSEC source: 0001209191-23-055560 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,301 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.15 to $0.1748, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 29, 2023 Filed Oct 2, 2023 19:02 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 193,960 | $0.16 | $30,742.66 |
DisclosureSEC source: 0001209191-23-051217 · doc4.xml · nonDerivative · entry 2 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 752,307 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of RSUs. This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · balance_after: A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 19:02 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantCommon Stock | 886,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051217 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 946,267 F1 · shares: The reported shares are represented by restricted stock units, or RSUs. 443,055 RSUs vested upon signing of the Agreement and Plan of Merger dated as of September 21, 2023, among Cyclo Therapeutics, Inc., a Nevada corporation, Cameo Merger Sub, Inc., a Delaware corporation and the Issuer (the "Merger Agreement"). The remaining 443,056 RSUs vest as to 50% on the date that is five trading days following the filing of the proxy/prospectus relating to stockholder approval of the merger contemplated by the Merger Agreement (the "Form S-4") and 50% on the date the Form S-4 is declared effective by the SEC. Read SEC document |
| September 05, 2023 Filed Oct 4, 2023 19:27 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 1,253 | $0.21 | $260.00 |
DisclosureSEC source: 0001209191-23-052122 · doc4.xml · nonDerivative · entry 4 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 746,748 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · balance_after: A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 02, 2023 Filed Oct 4, 2023 19:27 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 477 | $0.24 | $114.58 |
DisclosureSEC source: 0001209191-23-052122 · doc4.xml · nonDerivative · entry 3 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 748,001 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| June 02, 2023 Filed Oct 4, 2023 19:27 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 536 | $0.24 | $128.85 |
DisclosureSEC source: 0001209191-23-052122 · doc4.xml · nonDerivative · entry 2 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 748,478 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| June 02, 2023 Filed Oct 4, 2023 19:27 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 3,293 | $0.24 | $794.27 |
DisclosureSEC source: 0001209191-23-052122 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 749,014 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 21:11 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | GrantStock Option (Right to Buy) · Derivative | 668,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001209191-23-021327 · doc4.xml · derivative · entry 1 Cross Shawn · CIK 0001734779 · Director · CEO & Chair of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668,000 Underlying: Common Stock · 668,000 shares Expires 2033-03-23 F1 · derivative.exercise_date: 1/2 of the shares subject to the option shall be vested and exercisable on the date of grant and 1/24 of the remaining shares subject to the option shall vest monthly thereafter, provided that the reporting person remains a service provider to the issuer on each such vest date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:20 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 934 | $0.50 | $467.00 |
DisclosureSEC source: 0001209191-23-015778 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,156 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · balance_after: A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 16:56 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 3,893 | $1.05 | $4,088.04 |
DisclosureSEC source: 0001209191-22-060031 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,090 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · balance_after: A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 19:17 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 416 | $1.42 | $590.68 |
DisclosureSEC source: 0001209191-22-048870 · doc4.xml · nonDerivative · entry 2 Cross Shawn · CIK 0001734779 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,983 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · balance_after: A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 19:17 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 468 | $1.42 | $664.70 |
DisclosureSEC source: 0001209191-22-048870 · doc4.xml · nonDerivative · entry 1 Cross Shawn · CIK 0001734779 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,399 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · balance_after: A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 19:20 UTC | Applied Molecular Transport Inc. AMTI · Entity 95737 | SaleCommon Stock | 2,166 | $3.04 | $6,590.06 |
DisclosureSEC source: 0001209191-22-034352 · doc4.xml · nonDerivative · entry 2 Cross Shawn · CIK 0001734779 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,867 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.927 to 3.105, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.